| Website | xenome.com |
| Category | BioTech |
| Phone | 61-7-3720-8055 |
| enquiries@xenome.com | |
| Employees |
| TOTAL | $22.5M |
| FUNDING TOTAL | $22.5M |
| Venture Round, 4/05 Queensland BioCapital Funds | $2.5M |
| Venture Round, 11/07 Queensland BioCapital Funds Amylin Pharmaceuticals Innovis Investments | $10M |
| Venture Round, 4/10 Queensland BioCapital Funds GBS Ventures | $10M |
Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company’s lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.
